Position in SPRY
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$308,713
+$12,011 QoQ
Shares Held
38,445
+51.0% QoQ
Ownership
0.039%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SPRY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Belpointe Asset Management LLC holds $7,054,376 across 13 Biotechnology names. SPRY ranks #5 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
34,042 | $1,729,333 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,213 | $1,709,852 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,776 | $1,239,595 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
15,088 | $975,137 | |
| 5 | SPRY |
ARS Pharmaceuticals, Inc.
This page
|
38,445 | $308,713 | |
| 6 | GALT |
Galectin Therapeutics Inc
|
106,139 | $296,127 | |
| 7 | INCY |
Incyte Corp
|
2,742 | $258,077 | |
| 8 | KLRS |
Kalaris Therapeutics, Inc.
|
40,000 | $230,800 |
All Filings in SPRY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $308,713 | 38,445 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $296,702 | 25,468 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $189,543 | 18,860 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $302,286 | 17,323 | Shares | Sole | 2025-07-22 | |
| No filing history on record for this holder in this stock. | ||||||